Aldosterone Receptor Antagonism in Heart Failure

The renin‐angiotensin‐aldosterone system plays a major role in the pathophysiology of heart failure. Aldosterone is one of the central mediators involved in the cardiac remodeling process. Its classic effect in heart failure is attributed to mineralocorticoid receptor–mediated salt and fluid retention leading to increased afterload. New evidence demonstrates nonclassic effects of increased collagen synthesis and myocardial fibrosis resulting in left ventricular hypertrophy. Antagonism of aldosterone receptors with spironolactone benefits patients with severe heart failure, and eplerenone benefits those after myocardial infarction who have left ventricular dysfunction. Future research is directed at aldosterone antagonism in patients with mild‐to‐moderate heart failure, coronary artery disease treated with percutaneous coronary intervention, and nephropathy complicated by diabetes mellitus.

[1]  J. Beizer,et al.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[2]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[3]  N. Reichek,et al.  Hypertension and Left Ventricular Hypertrophy : The 4 E Effects of Eplerenone , Enalapril , and Eplerenone / Enalapril in Patients With Essential , 2003 .

[4]  S. Oparil,et al.  Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. , 2003, Clinical therapeutics.

[5]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[6]  W. White,et al.  Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. , 2003, The American journal of cardiology.

[7]  M. Horie,et al.  Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction , 2003, Circulation.

[8]  S. Oparil,et al.  Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. , 2003, Journal of the American College of Cardiology.

[9]  S. Koenig,et al.  Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). , 2003, Heart disease.

[10]  J. Funder.  New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. , 2002, American heart journal.

[11]  H. Krum,et al.  Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients , 2002, Hypertension.

[12]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[13]  J. Funder.  MINERALOCORTICOIDS AND CARDIAC FIBROSIS: THE DECADE IN REVIEW , 2001, Clinical and experimental pharmacology & physiology.

[14]  M. Epstein,et al.  Aldosterone as a Determinant of Cardiovascular and Renal Dysfunction , 2001, Journal of the Royal Society of Medicine.

[15]  M. Ward,et al.  Eplerenone Suppresses Constrictive Remodeling and Collagen Accumulation After Angioplasty in Porcine Coronary Arteries , 2001, Circulation.

[16]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[17]  H. Müderrisoğlu,et al.  Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. , 2000, The American journal of cardiology.

[18]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[19]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[20]  C. Rapezzi.  [Comparison of candesartan, enalapril and their combination in congestive heart failure]. , 2000, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[21]  A. Struthers,et al.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. , 2000, Circulation.

[22]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[23]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[24]  A. Ciampi,et al.  Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. , 1998, European heart journal.

[25]  A. Struthers,et al.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.

[26]  C. Lang,et al.  Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. , 1995, The American journal of cardiology.

[27]  N. Farman,et al.  Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. , 1995, Circulation.

[28]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[29]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[30]  J. Staessen,et al.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.

[31]  T. Diperri,et al.  Aldosterone in congestive heart failure. , 1959, Acta medica Scandinavica.

[32]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.